Related Experiment Video

Updated: Dec 26, 2025

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.2K

ctDNA Reveals Targetable Alterations

    Cancer Discovery
    |March 13, 2020
    PubMed

    Insights

    In the plasmaMATCH trial, patients with advanced breast cancer received targeted therapies based on circulating tumor DNA testing. HER2 and AKT1 mutations showed promising response rates over 22% with lasting benefits.

    Area of Science:

    • Oncology
    • Genomics
    • Pharmacology

    Background:

    • Advanced breast cancer presents significant treatment challenges.
    • Genetic alterations like ESR1, HER2, and AKT1 impact treatment efficacy.
    • Circulating tumor DNA (ctDNA) analysis offers a non-invasive method for identifying actionable mutations.

    More Related Videos

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    7.7K
    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids06:53

    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

    Published on: June 8, 2019

    9.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.6K
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    6.2K